Acurx pharmaceuticals inc ACXP.US 總覽分析

美股醫療保健
(ACXP 無簡報檔)

ACXP 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼

ACXP 近期報酬表現

9.83%

Acurx pharmaceuticals inc

4.57%

同產業平均

3.26%

S&P500

與 ACXP 同產業的標的表現

  • TPST Tempest therapeutics inc
    價值 2 分趨勢 2 分波段 4 分籌碼 1 分股利 1 分
    查看更多

ACXP 公司資訊

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

ACXP 股價